Short answer · Medically reviewed summary · Last updated: 2023-07-13
Tyrosinemia Type I is a rare genetic disorder characterized by the deficiency of the enzyme fumarylacetoacetate hydrolase (FAH), which is essential for the breakdown of the amino acid tyrosine. This leads to the accumulation of toxic byproducts in the body, causing severe liver and kidney damage if left untreated. The prevalence of Tyrosinemia Type I varies among different populations.
What is the prevalence of Tyrosinemia Type I?
Prevalence of Tyrosinemia Type I: how many people are affected worldwide, differences by sex and region, with sources.
Tyrosinemia Type I is a rare genetic disorder characterized by the deficiency of the enzyme fumarylacetoacetate hydrolase (FAH), which is essential for the breakdown of the amino acid tyrosine. This leads to the accumulation of toxic byproducts in the body, causing severe liver and kidney damage if left untreated.
The prevalence of Tyrosinemia Type I varies among different populations. It is estimated to affect approximately 1 in 100,000 to 120,000 individuals worldwide. However, the prevalence may be higher in certain regions or communities where consanguineous marriages are more common.
Due to its rarity, Tyrosinemia Type I is considered an orphan disease. It is typically diagnosed in infancy or early childhood, as affected infants may exhibit failure to thrive, liver dysfunction, and other symptoms. Early detection and prompt treatment are crucial to prevent life-threatening complications.
Treatment for Tyrosinemia Type I involves a strict low-protein diet, medication, and in severe cases, liver transplantation. With appropriate management, individuals with Tyrosinemia Type I can lead relatively normal lives, although long-term monitoring and adherence to dietary restrictions are necessary.
